EDEN PRAIRIE, Minn., April 10, 2024 (GLOBE NEWSWIRE) -- Elucent Medical, a pioneering medical technology company transforming the field of surgical navigation through In-Site Spatial Intelligence (iSI) is pleased to announce the successful closure of its $42.5 million Series C funding round. The proceeds will further propel the development and commercialization of its groundbreaking EnVisio® and SmartClip® technologies for tissue sparing oncologic surgery. The financing was led by Vensana Capital and RC Capital with participation from existing investors. This investment validates the growing interest in Elucent's transformative approach to enhancing precision and efficacy in cancer surgery. Elucent's flagship technologies, EnVisio® and SmartClip®, offer precision In-Site Spatial Intelligence during oncologic procedures. EnVisio® leverages proprietary technology that converts existing surgical tools to smart navigated instruments that can be tracked in real-time and guided with millimeter precision. EnVisio is currently optimized to guide the surgical treatment of breast cancer, while adoption of the technology has expanded to address other soft tissue oncology surgeries. In addition, Elucent is currently developing products to assist surgeons in their pursuit of margin negative resections in lung and other soft tissue clinical applications, and these products also integrate with existing tools and minimally invasive solutions, including video and robotic-assisted medical ...